FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062654769> ?p ?o ?g. }

• W2062654769 endingPage "1083" @default.
• W2062654769 startingPage "1073" @default.
• W2062654769 abstract "Objective Antibodies to human papillomavirus are indicative for previous human papillomavirus exposure. Human papillomavirus antibody reactivities to vulvar precancerous lesions were reported poorly, and the role of human papillomavirus in some of these lesions is still unclear. Study design In a direct enzyme-linked immunosorbent assay, serum samples from 126 healthy control subjects, 97 women with lichen sclerosus with or without squamous hyperplasia, 78 women with vulvar intraepithelial neoplasia, and 16 women with verrucous carcinoma were examined for immunoglobulin G and A antibodies to L1 virus-like particles of genital human papillomavirus types 6, 11, 16, 18, and 31, cutaneous human papillomavirus type 8, bovine papilloma virus, and cottontail rabbit papilloma virus. Results In lichen sclerosus/squamous hyperplasia with atypia immunoglobulin G and A, antibody positivity rates to high-risk human papillomavirus virus-like particle types 16, 18, and 31 were significantly higher than in the control group and the lichen sclerosus/squamous hyperplasia group without atypia. In patients with vulvar intraepithelial neoplasia I, increased immunoglobulin G antibody prevalences with both high-risk and low-risk human papillomavirus–virus-like particles were detected; whereas in patients with vulvar intraepithelial neoplasia II/III, this was observed only with the human papillomavirus types 16, 18, and 31. When only reactivities with 2 genital human papillomavirus types were compared, percentages of positives to only 1 of these 2 types ranged between 43% and 82%, with regard to all respective positives. Conclusion Our data support the role of high-risk human papillomavirus types, mainly human papillomavirus-16, in the pathogenesis of different vulvar lesions with atypia. Serologically, there are no indications that lichen sclerosus/squamous hyperplasia without atypia is associated with human papillomavirus, but high-risk human papillomavirus in lichen sclerosus/squamous hyperplasia with atypia could play a role in carcinogenesis. High antibody specificity was clearly demonstrated among 5 genital, 1 cutaneous human, and 2 animal papillomavirus types. Antibodies to human papillomavirus are indicative for previous human papillomavirus exposure. Human papillomavirus antibody reactivities to vulvar precancerous lesions were reported poorly, and the role of human papillomavirus in some of these lesions is still unclear. In a direct enzyme-linked immunosorbent assay, serum samples from 126 healthy control subjects, 97 women with lichen sclerosus with or without squamous hyperplasia, 78 women with vulvar intraepithelial neoplasia, and 16 women with verrucous carcinoma were examined for immunoglobulin G and A antibodies to L1 virus-like particles of genital human papillomavirus types 6, 11, 16, 18, and 31, cutaneous human papillomavirus type 8, bovine papilloma virus, and cottontail rabbit papilloma virus. In lichen sclerosus/squamous hyperplasia with atypia immunoglobulin G and A, antibody positivity rates to high-risk human papillomavirus virus-like particle types 16, 18, and 31 were significantly higher than in the control group and the lichen sclerosus/squamous hyperplasia group without atypia. In patients with vulvar intraepithelial neoplasia I, increased immunoglobulin G antibody prevalences with both high-risk and low-risk human papillomavirus–virus-like particles were detected; whereas in patients with vulvar intraepithelial neoplasia II/III, this was observed only with the human papillomavirus types 16, 18, and 31. When only reactivities with 2 genital human papillomavirus types were compared, percentages of positives to only 1 of these 2 types ranged between 43% and 82%, with regard to all respective positives. Our data support the role of high-risk human papillomavirus types, mainly human papillomavirus-16, in the pathogenesis of different vulvar lesions with atypia. Serologically, there are no indications that lichen sclerosus/squamous hyperplasia without atypia is associated with human papillomavirus, but high-risk human papillomavirus in lichen sclerosus/squamous hyperplasia with atypia could play a role in carcinogenesis. High antibody specificity was clearly demonstrated among 5 genital, 1 cutaneous human, and 2 animal papillomavirus types." @default.
• W2062654769 created "2016-06-24" @default.
• W2062654769 creator A5009502778 @default.
• W2062654769 creator A5025519748 @default.
• W2062654769 creator A5035962444 @default.
• W2062654769 creator A5042680669 @default.
• W2062654769 creator A5049644371 @default.
• W2062654769 creator A5065112517 @default.
• W2062654769 creator A5078737376 @default.
• W2062654769 creator A5089069429 @default.
• W2062654769 date "2005-04-01" @default.
• W2062654769 modified "2023-10-15" @default.
• W2062654769 title "Specific serologic response to genital human papillomavirus types in patients with vulvar precancerous and cancerous lesions" @default.
• W2062654769 cites W1919752763 @default.
• W2062654769 cites W1985584979 @default.
• W2062654769 cites W1986130929 @default.
• W2062654769 cites W1986386086 @default.
• W2062654769 cites W1999597014 @default.
• W2062654769 cites W2001980141 @default.
• W2062654769 cites W2027215225 @default.
• W2062654769 cites W2034530626 @default.
• W2062654769 cites W2036593962 @default.
• W2062654769 cites W2054699629 @default.
• W2062654769 cites W2066029482 @default.
• W2062654769 cites W2070427486 @default.
• W2062654769 cites W2085429487 @default.
• W2062654769 cites W2088457548 @default.
• W2062654769 cites W2089002771 @default.
• W2062654769 cites W2096830665 @default.
• W2062654769 cites W2113590402 @default.
• W2062654769 cites W2135880251 @default.
• W2062654769 cites W2152959169 @default.
• W2062654769 cites W2171783306 @default.
• W2062654769 cites W3143504308 @default.
• W2062654769 cites W4362208337 @default.
• W2062654769 cites W82698608 @default.
• W2062654769 doi "https://doi.org/10.1016/j.ajog.2004.09.130" @default.
• W2062654769 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15846183" @default.
• W2062654769 hasPublicationYear "2005" @default.
• W2062654769 type Work @default.
• W2062654769 sameAs 2062654769 @default.
• W2062654769 citedByCount "13" @default.
• W2062654769 countsByYear W20626547692012 @default.
• W2062654769 countsByYear W20626547692015 @default.
• W2062654769 countsByYear W20626547692017 @default.
• W2062654769 countsByYear W20626547692020 @default.
• W2062654769 countsByYear W20626547692022 @default.
• W2062654769 crossrefType "journal-article" @default.
• W2062654769 hasAuthorship W2062654769A5009502778 @default.
• W2062654769 hasAuthorship W2062654769A5025519748 @default.
• W2062654769 hasAuthorship W2062654769A5035962444 @default.
• W2062654769 hasAuthorship W2062654769A5042680669 @default.
• W2062654769 hasAuthorship W2062654769A5049644371 @default.
• W2062654769 hasAuthorship W2062654769A5065112517 @default.
• W2062654769 hasAuthorship W2062654769A5078737376 @default.
• W2062654769 hasAuthorship W2062654769A5089069429 @default.
• W2062654769 hasConcept C121608353 @default.
• W2062654769 hasConcept C126322002 @default.
• W2062654769 hasConcept C138055712 @default.
• W2062654769 hasConcept C142724271 @default.
• W2062654769 hasConcept C159654299 @default.
• W2062654769 hasConcept C203014093 @default.
• W2062654769 hasConcept C2776235491 @default.
• W2062654769 hasConcept C2776316342 @default.
• W2062654769 hasConcept C2776552008 @default.
• W2062654769 hasConcept C2777343196 @default.
• W2062654769 hasConcept C2778220009 @default.
• W2062654769 hasConcept C2779534503 @default.
• W2062654769 hasConcept C2781076405 @default.
• W2062654769 hasConcept C2781283455 @default.
• W2062654769 hasConcept C71924100 @default.
• W2062654769 hasConceptScore W2062654769C121608353 @default.
• W2062654769 hasConceptScore W2062654769C126322002 @default.
• W2062654769 hasConceptScore W2062654769C138055712 @default.
• W2062654769 hasConceptScore W2062654769C142724271 @default.
• W2062654769 hasConceptScore W2062654769C159654299 @default.
• W2062654769 hasConceptScore W2062654769C203014093 @default.
• W2062654769 hasConceptScore W2062654769C2776235491 @default.
• W2062654769 hasConceptScore W2062654769C2776316342 @default.
• W2062654769 hasConceptScore W2062654769C2776552008 @default.
• W2062654769 hasConceptScore W2062654769C2777343196 @default.
• W2062654769 hasConceptScore W2062654769C2778220009 @default.
• W2062654769 hasConceptScore W2062654769C2779534503 @default.
• W2062654769 hasConceptScore W2062654769C2781076405 @default.
• W2062654769 hasConceptScore W2062654769C2781283455 @default.
• W2062654769 hasConceptScore W2062654769C71924100 @default.
• W2062654769 hasIssue "4" @default.
• W2062654769 hasLocation W20626547691 @default.
• W2062654769 hasLocation W20626547692 @default.
• W2062654769 hasOpenAccess W2062654769 @default.
• W2062654769 hasPrimaryLocation W20626547691 @default.
• W2062654769 hasRelatedWork W1602735152 @default.
• W2062654769 hasRelatedWork W1808981406 @default.
• W2062654769 hasRelatedWork W2002491669 @default.
• W2062654769 hasRelatedWork W2094164532 @default.
• W2062654769 hasRelatedWork W2121051971 @default.
• W2062654769 hasRelatedWork W2137876451 @default.
• W2062654769 hasRelatedWork W2342458645 @default.

• next